Erazaban, 10% cream 2 g

Indications

Skin infections caused by the Herpes simplex virus type 1 (including herpes labialis) in immunocompetent patients.

Pharmacological effect

Pharmaceutical group:

Antiviral drug for external use.

Pharmaceutical action:

Erazaban is an antiviral agent. The exact mechanism of antiviral action is unclear. In vitro studies have shown that docosanol affects the adhesion of the virus to the plasma membrane, which inhibits viral entry into the cell and its replication. In vivo studies have shown that cells treated with docosanol are resistant to infection by lipid-enveloped viruses such as Herpes simplex virus 1. Docosanol has no effect against non-enveloped viruses.

Docosanol 10% cream has been studied in clinical trials compared to placebo (containing polyethylene glycol). A total of 737 patients were randomized. The mean time to complete recovery was 4.1 days in the docosanol group and 4.8 days in the placebo group, with a difference of 17.5 hours (0.7 days).

Pharmacokinetics:

Docosanol is metabolized intracellularly to docosanic acid (the main metabolite). Docosanol and its metabolite are endogenous components of cell membranes in humans, especially in red blood cells, brain, lungs and kidneys.

When applying the cream on intact skin: absorption is minimal, not detected in the blood. Affected skin: absorption is moderate. Excreted by the kidneys.

Special instructions

The drug Erazaban is intended for external use only!

Avoid contact of the drug with the eyes; do not apply to the skin near the eyes.

To achieve the maximum therapeutic effect, it is necessary to use the drug at the first signs of the disease (burning, itching, tingling, feeling of tension and redness).

This product contains propylene glycol and may cause skin irritation. The cream should not be used in patients with weakened immune systems.

Influence on the ability to drive vehicles and machinery. No effect.

Active ingredient

Docosanol

Composition

1 g of cream for external use contains:

active ingredient:

docosanol 100 mg,

excipients:

sucrose – 50 mg;

mineral oil – 80 mg;

propylene glycol – 50 mg;

benzyl alcohol – 27 mg;

water – 693 mg

Pregnancy

Preclinical studies in animals did not reveal a teratogenic embryotoxic effect on the fetus.

Before using Erazaban during pregnancy or breastfeeding, consult a doctor.

Contraindications

Hypersensitivity to docosanol or any other component of Erazaban; age up to 12 years (no experience of use).

With caution: pregnancy and lactation.

Side Effects

Headache; in areas where the drug is applied – dry skin, itching, rash, short-term redness, soreness, peeling, burning or tingling.

These side effects, as a rule, do not require discontinuation of the drug.

There are isolated reports of cases of angioedema with external use of the drug.

If any of the side effects indicated in the description worsen or the patient notices any other side effects not listed in the description, the doctor should be informed.

Interaction

When used externally, no interactions with other drugs were detected.

An enhanced effect is observed with the simultaneous administration of immunostimulants.

Overdose

No cases of drug overdose have been reported.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

3 years. After first opening, store for no more than 6 months.

Manufacturer

Fleet Laboratories Limited, UK